Pharnext, a clinical-stage biopharma company developing drug combinations based on big genomic data and artificial intelligence (AI), and the University Hospital Institute Méditerranée Infection, devoted to infectious and tropical diseases in France, have partnered to research potential drug candidates to fight COVID-19 virus.

The joint activities will focus on rapidly testing in vitro a number of already approved drugs that were previously identified by Pharnext as potential candidates for fighting COVID-19 using its PLEOTHERAPY AI platform. The testing will also include several high priority drug combination candidates against COVID-19, also using the PLEOTHERAPY AI platform. The testing will be performed by the UHI Méditerranée Infection in preclinical studies.

"We anticipate that with such an efficient and highly qualified team, important in vitro results will be forthcoming" said Daniel Cohen, M.D., Ph.D., Founder and President of the Scientific Advisory Board of Pharnext.

"We are all engaged in the same medical fight to treat COVID-19 patients as fast as possible to slow down the epidemic and prevent, treat severe forms of the disease" said Didier Raoult, M.D., Ph.D., Founder and Head of the UHI Méditerranée Infection.
 

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.